Friday, September 30, 2022


Biotechnology News Magazine

Invizius Awarded Second Biomedical Catalyst Grant to Research Peritoneal Dialysis Option for its H-Guard® Technology

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Invizius Limited (“Invizius”), a biotechnology company developing treatments to suppress unwanted immune responses in hemodialysis, today announces that it has been awarded a second Biomedical Catalyst grant (Feasibility & Primer Award) by Innovate UK to research a new field of application for its H-Guard® technology.

Globally there are 3.5 million patients who are solely dependent on renal replacement therapy to preserve life. These figures are increasing due to the rising incidence of chronic kidney disease, diabetes, and acute kidney injury. Haemodialysis and Peritoneal Dialysis are the two main treatment methods used today. Both have limitations due to the body’s immune reaction to the procedure.

Today Invizius is developing its H-Guard Haemodialysis Priming Solution which comprises a novel protein that lines the inside of the dialysis filter and helps dialysis to take place undetected by the body’s immune system. This suppresses the blood’s foreign body response preventing a repetitive, hostile inflammatory reaction that increases the risk of cardiovascular and other complications.

Peritoneal Dialysis (PD) offers considerable benefits to patients, but it has a high dropout rate, which has limited its adoption compared to Haemodialysis. One of the main causes of dropout is damage to the peritoneal membrane from chronic exposure to PD solutions, and immune activation is thought to be a key driver.

Invizius will now assess in-vitro and in-vivo efficacy of a novel method of using its technology for PD and progress thereafter into pre-clinical development. The project will run for 18 months.

Dr. Andy Herbert, Chief Technology Officer of Invizius, said: “Our Board, which comprises members with significant industry experience, together with key PD opinion leaders have encouraged us to assess how our H-Guard technology could be applied to minimise peritioneal membrane damage, a key issue for PD therapy. We are very pleased to receive this second Biomedical Catalyst grant which will allow us to research ways of addressing this issue alongside our Haemodialysis development programme which is running on track.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine